ACE ImmunoID™: End-to-End Neoantigen Discovery

Personalis®

Neoantigen selection is complex. The ACE ImmunoID Platform, which uses Personalis' patented ACE Technology™, combines augmented exome and transcriptome sequencing with analytics to enable broad tumor immunogenomic characterization. NeoantigenID™, a component of the ACE ImmunoID platform, provides you with detailed analytics for comprehensive neoantigen determination.

Whole Exome & Whole Transcriptome Sequencing

With **>8,000** Biomedically relevant genes augmented

Analytically Validated

**200x** Coverage

Matched Tumor/Normal Analysis

NeoantigenID™ (RUO)

- IDs neoantigens from **SNVs**, **indels**, and **fusions**
- **MHC Class I** and **Class II** peptide binding affinity
- **TMB** and **neoantigen load**
- **Allelic fraction** and **allele-specific expression**
- **Phasing** for more accurate neoantigen determination

* At 10% mutant allele frequencies for small variants
‡ 22/23 experimentally-validated neoantigens correctly predicted

Exome*

97% Sensitivity

98% Specificity

Transcriptome*

97% Sensitivity

Neoantigen Prediction‡

96% Sensitivity

Analytically Validated HLA Typing:

>95% Class I, >95% Class II

Ready to accelerate your personalized cancer vaccine development? Contact us at **info@personalis.com**.

101-003-C